Module 6 questions - Safer aminoglycoside dosage (Clinical challenge)
  1. The Cave value is the same for both simulations. Why is this so?
  2. Which regimen is more certain to produce bactericidal concentrations? Remember, you are unlikely to KNOW the MBC for a particular bacterial infection. You are interested in improving the ODDS that the bacteria is exposed to sufficiently high concentrations.
  3. If you do not know the patient's renal status, which regimen is less likely to result in toxicity?
  4. Which regimen is more likely allows the plasma concentrations to fall so low that the bacteria start to regrow at the end of each dose interval?